Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Axsome Therapeutics, Inc. (AXSM : NSDQ)
 
 • Company Description   
Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

Number of Employees: 108

 
 • Price / Volume Information   
Yesterday's Closing Price: $31.51 Daily Weekly Monthly
20 Day Moving Average: 1,182,521 shares
Shares Outstanding: 38.91 (millions)
Market Capitalization: $1,226.17 (millions)
Beta: 2.47
52 Week High: $74.10
52 Week Low: $19.38
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.43% -10.38%
12 Week 12.06% 23.20%
Year To Date -16.60% 1.91%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
22 CORTLANDT STREET 16TH FLOOR
-
NEW YORK,NY 10007
USA
ph: 212-332-3241
fax: 212-320-0245
None http://axsome.com
 
 • General Corporate Information   
Officers
Herriot Tabuteau - Chief Executive Officer and Chairman
Nick Pizzie - Chief Financial Officer
Roger Jeffs - Director
Mark Coleman - Director
Mark Saad - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 05464T104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 38.91
Most Recent Split Date: (:1)
Beta: 2.47
Market Capitalization: $1,226.17 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 83.42
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -32.05%
vs. Previous Quarter: -14.44%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -389.71
12/31/21 - -230.72
09/30/21 - -154.94
ROA
03/31/22 - -129.08
12/31/21 - -101.37
09/30/21 - -81.96
Current Ratio
03/31/22 - 3.54
12/31/21 - 3.75
09/30/21 - 4.66
Quick Ratio
03/31/22 - 3.54
12/31/21 - 3.75
09/30/21 - 4.66
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.38
12/31/21 - 0.41
09/30/21 - 1.13
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 3.36
12/31/21 - 3.14
09/30/21 - 1.15
Debt-to-Capital
03/31/22 - 77.04
12/31/21 - 75.85
09/30/21 - 53.51
 

Powered by Zacks Investment Research ©